CL2012003010A1 - Tableta enterica que comprende un núcleo de 4-[2-(4-metilfenilsulfanil)fenil]piperidina y una capa de recubrimiento enterico que comprende uno o mas componentes polimericos tal como copolimero de acido metacrilico, y talco en una proporcion menor o igual al 40% del componente polimerico, basicamente sin componente alcalino. - Google Patents

Tableta enterica que comprende un núcleo de 4-[2-(4-metilfenilsulfanil)fenil]piperidina y una capa de recubrimiento enterico que comprende uno o mas componentes polimericos tal como copolimero de acido metacrilico, y talco en una proporcion menor o igual al 40% del componente polimerico, basicamente sin componente alcalino.

Info

Publication number
CL2012003010A1
CL2012003010A1 CL2012003010A CL2012003010A CL2012003010A1 CL 2012003010 A1 CL2012003010 A1 CL 2012003010A1 CL 2012003010 A CL2012003010 A CL 2012003010A CL 2012003010 A CL2012003010 A CL 2012003010A CL 2012003010 A1 CL2012003010 A1 CL 2012003010A1
Authority
CL
Chile
Prior art keywords
enteric
methylphenylsulfanyl
talc
basically
phenyl
Prior art date
Application number
CL2012003010A
Other languages
English (en)
Inventor
Masafumi Misaki
Yuki Tsushima
Masahiro Niwa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CL2012003010A1 publication Critical patent/CL2012003010A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Tableta entérica que comprende un núcleo de 4-[2-(4-metilfenilsulfanil)fenil]piperidina y una capa de recubrimiento entérico que comprende uno o más componentes poliméricos tal como copolímero de ácido metacrílico, y talco en una proporción menor o igual al 40% del componente polimérico, básicamente sin componente alcalino.
CL2012003010A 2010-04-30 2012-10-26 Tableta enterica que comprende un núcleo de 4-[2-(4-metilfenilsulfanil)fenil]piperidina y una capa de recubrimiento enterico que comprende uno o mas componentes polimericos tal como copolimero de acido metacrilico, y talco en una proporcion menor o igual al 40% del componente polimerico, basicamente sin componente alcalino. CL2012003010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010105668 2010-04-30

Publications (1)

Publication Number Publication Date
CL2012003010A1 true CL2012003010A1 (es) 2013-04-01

Family

ID=44861665

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003010A CL2012003010A1 (es) 2010-04-30 2012-10-26 Tableta enterica que comprende un núcleo de 4-[2-(4-metilfenilsulfanil)fenil]piperidina y una capa de recubrimiento enterico que comprende uno o mas componentes polimericos tal como copolimero de acido metacrilico, y talco en una proporcion menor o igual al 40% del componente polimerico, basicamente sin componente alcalino.

Country Status (14)

Country Link
US (1) US8920840B2 (es)
EP (1) EP2564837B1 (es)
JP (1) JP5787881B2 (es)
KR (1) KR20130060220A (es)
CN (1) CN103096879B (es)
BR (1) BR112012027782A2 (es)
CA (1) CA2797809A1 (es)
CL (1) CL2012003010A1 (es)
CO (1) CO6650343A2 (es)
ES (1) ES2723029T3 (es)
GE (1) GEP20166487B (es)
IL (1) IL222753A (es)
RU (1) RU2593771C2 (es)
WO (1) WO2011136373A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102970982B (zh) * 2010-04-30 2015-01-14 武田药品工业株式会社 肠溶片剂
TWI710379B (zh) 2015-07-30 2020-11-21 日商武田藥品工業股份有限公司 錠劑
EP3184102A1 (en) * 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
CN109893511B (zh) * 2017-12-11 2022-07-12 湖北舒邦药业有限公司 一种地红霉素肠溶片肠溶包衣、其制备方法以及一种地红霉素肠溶片
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
EP0520119A1 (de) 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
WO1998027967A1 (en) 1996-12-20 1998-07-02 Dumex-Alpharma A/S Release-controlled coated tablets
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001058424A1 (en) 2000-02-09 2001-08-16 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Floating drug delivery composition
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DK1443917T3 (da) 2001-11-07 2006-07-17 Synthon Bv Tamsulosintabletter
US20050025824A1 (en) 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20060210633A1 (en) 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
JP4667366B2 (ja) * 2003-04-04 2011-04-13 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤としての４−（２−フェニルスルファニル−フェニル）−ピペリジン誘導体
CN100563648C (zh) 2003-04-25 2009-12-02 田边三菱制药株式会社 包含亚烷基二氧苯衍生物的口服组合物
JP2007504266A (ja) * 2003-09-02 2007-03-01 ファイザー・プロダクツ・インク ジプラシドンの持続放出剤形
MXPA06004700A (es) 2003-10-31 2006-07-05 Hexal Ag Formulacion conteniendo agente farmaceutico comprendiendo un recubrimiento.
WO2005046648A1 (en) 2003-11-12 2005-05-26 Glenmark Pharmaceuticals Ltd. Extended release pharmaceutical dosage forms comprising alpha-2 agonist tizanidine
US20050244490A1 (en) 2003-12-09 2005-11-03 Michael Otto Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
IL160095A0 (en) 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
KR100582350B1 (ko) 2004-02-17 2006-05-22 한미약품 주식회사 탐수로신 염산염의 경구투여용 조성물 및 이의 서방성과립 제제
US20060008520A1 (en) 2004-04-01 2006-01-12 Lerner E I Delayed release formulations of 6-mercaptopurine
WO2005105036A1 (en) 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
RU2382637C2 (ru) 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
US20060018957A1 (en) 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
TW200626185A (en) * 2004-12-17 2006-08-01 Bpsi Holdings Inc Enteric film coating composition containing entericpolymer micronized with detackifier
EP1888257A1 (en) * 2005-05-05 2008-02-20 Pulmatrix, Inc. Ultrasonic aerosol generator
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
TW200836774A (en) * 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
KR101122447B1 (ko) 2007-11-09 2012-03-20 미쓰비시 타나베 파마 코퍼레이션 신규 제제
TW200938194A (en) 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
JP5195284B2 (ja) 2008-10-28 2013-05-08 富士レビオ株式会社 試薬容器のキャップ構造および試薬の分取方法
DK2470166T3 (da) 2009-08-24 2013-09-08 Lundbeck & Co As H Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin

Also Published As

Publication number Publication date
ES2723029T3 (es) 2019-08-21
CN103096879B (zh) 2014-12-10
EP2564837B1 (en) 2019-01-30
RU2593771C2 (ru) 2016-08-10
GEP20166487B (en) 2016-06-10
US20130115291A1 (en) 2013-05-09
US8920840B2 (en) 2014-12-30
IL222753A (en) 2017-09-28
JPWO2011136373A1 (ja) 2013-07-22
BR112012027782A2 (pt) 2016-08-02
JP5787881B2 (ja) 2015-09-30
RU2012151315A (ru) 2014-06-10
CO6650343A2 (es) 2013-04-15
KR20130060220A (ko) 2013-06-07
EP2564837A4 (en) 2014-06-18
CA2797809A1 (en) 2011-11-03
IL222753A0 (en) 2012-12-31
EP2564837A1 (en) 2013-03-06
WO2011136373A1 (ja) 2011-11-03
CN103096879A (zh) 2013-05-08

Similar Documents

Publication Publication Date Title
CL2012003010A1 (es) Tableta enterica que comprende un núcleo de 4-[2-(4-metilfenilsulfanil)fenil]piperidina y una capa de recubrimiento enterico que comprende uno o mas componentes polimericos tal como copolimero de acido metacrilico, y talco en una proporcion menor o igual al 40% del componente polimerico, basicamente sin componente alcalino.
CL2012003028A1 (es) Tableta entérica que comprende: 1) 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina o sus sales y 2) una capa de recubrimiento entérico que comprende a) uno o mas componentes poliméricos como copolímero de ácido metacrílico, b) talco y c) sin componente alcalino, útil en el tratamiento de trastornos del humor como depresión o ansiedad.
CL2013001793A1 (es) Comprimido de desintegracion oral de liberacion controlada que comprende i) granulos que contienen lanzoprazol y una capa de recubrimiento que comprende un copolimero y ii) granulos que comprenden lanzoprazol y una capa de recubrimiento que comprende un copolimero y un polimero, con granulos de tamaño medio de no mas de 500 µm.
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
CO6640208A2 (es) Composiciones solidas
ES2530626T3 (es) Resinas de benzoxazina
BR112013015104A2 (pt) arranjo de peneira de poço
CR20120254A (es) Células madre multipotenciales en el árbol de billary extrahepática y métodos de aislamiento del mismo
CL2012000825A1 (es) Compuestos derivados de 4-(indan-2-iloxi)-pirimidin-2-il-amino, 4-(ciclopentiloxi)-pirimidin-2-il-amino, 4-(ciclohexiloxi)-pirimidin-2-il-amino, inhibidores de la enzima ptk2, con una accion antiangiogenica; composicion farmaceutica; utiles para el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
DK2109173T3 (da) Fastoxid brændselscellestak, fremgangsmåde til fremstilling heraf og anvendelse af en E-glas deri
CL2007002618A1 (es) Composicion farmaceutica de liberacion modificada oral que comprende una pluralidad de mini-comprimidos con un diametro menor que 5 mm y comprendiendo un inhibidor del factor xa dentro de una matriz de uno o mas polimeros; procedimiento de preparacio
CL2015000544A1 (es) Una composicion farmaceutica que comprende regorafenib y al menos un excipiente farmaceuticamente aceptable, en el que la composicion esta recubierta por un recubrimiento que comprende un polimero basado en alcohol polivinilico; y su procedimiento de preparacion.
CL2017002092A1 (es) Modificación del sitio de unión del represor transcripcional del promotor nf-yc4 para un contenido de proteína aumentado y resistencia al estrés
BR112014019764A8 (pt) Composição
MA32818B1 (fr) Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
ES2623281T3 (es) Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones.
ITMI20061763A1 (it) Procedimento perfezionato di avvolgimento del filato in rocca con dispositivi guidafili individuali
CL2013000089A1 (es) Tableta de desintegracion rapida en la cavidad oral que contiene particulas nucleares con acido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazolcarboxilico y que estan recubiertas con dos capas.
AR084081A1 (es) Pintura arquitectural para cubrir defectos
MX351608B (es) Compensador de grosor de tejidos que comprende canales.
RS53620B1 (en) USE OF 4- [ETHYL (DIMETHYL) AMONIO] BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE
BRPI0914808A2 (pt) composição contendo polímero e copolimero metacrílico tendo grupos associados
BR112013007421A2 (pt) composição adesiva
IL239928B (en) Preparations containing (s)-1-(4-(4-(4,3-dichlorophenyl(piperidino-(3-(2-(5-methyl4,3,1-oxodiazol-2-yl)-benzo[b]furan -4-yloxy-2-propanol for the treatment of depression